Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drug combination might offer hope for patients deadly brain tumors

22.10.2007
Brain cancer patients with the poorest prognosis -- those with a type of deadly tumor known as glioblastoma multiforme (GBM) -- may survive longer with a drug that chokes off a tumor’s blood supply.

According to a new study by researchers at Duke’s Preston Robert Tisch Brain Tumor Center, a combination of bevacizumab -- commonly known as Avastin -- and a standard chemotherapy agent, may increase the amount of time GBM patients can survive without tumor growth, and may significantly increase their overall survival.

“For this study, we looked at patients whose tumors had returned after initial treatment, and we found that this drug combination could significantly improve outcomes for these people, who are typically given about three to six months to live,” said James J. Vredenburgh, M.D., a neuro-oncologist at Duke and lead investigator on the study. “These results represent tremendous hope for these patients and their families.”

The researchers published their findings in the October 20, 2007 issue of the Journal of Clinical Oncology and an editorial accompanied the publication. The study was funded by the National Institutes of Health, the Preston Robert Tisch Brain Tumor Research Fund and the Bryan Cless Research Fund.

In this pilot study, researchers administered a combination of bevacizumab and irinotecan, a standard chemotherapeutic agent, to 35 patients whose GBMs had returned. Each patient had already been treated with a standard therapy regimen, possibly including surgery, radiation and chemotherapy.

Almost half saw no tumor progression after six months, and almost 80 percent were still alive six months after diagnosis.

Patients with recurrent GBM who are treated with standard therapies, such as chemotherapy alone, have tumor progression at six months in about 75 percent of cases and fewer than 50 percent are alive after six months.

“Historically, when GBM recurred, there had typically been very little else we could do,” said Vredenburgh. “We had one patient on this trial who had been already been told to get his affairs in order; he started the trial and over a year later he’s still here, so this is very promising.”

Bevacizumab has been heralded as a success in treating several types of cancer, including colorectal and lung cancers. It is one member of a class of drugs called anti-angiogenics, which work by stunting the otherwise rapid growth of blood vessels that feed a tumor’s growth and spread.

“We speculate that bevacizumab and irinotecan each attack a particular characteristic of the tumor independently or they work together, with the bevacizumab suppressing the growth of blood vessels which makes the tumor more susceptible to the chemotherapy,” Vredenburgh said. “Further studies will tease out the exact mechanism of the therapy’s success and we also hope to study the effectiveness of this treatment in patients with newly diagnosed GBM.”

About 8,000 to 10,000 new cases of GBM are diagnosed each year in the United States, and GBMs account for about half of all primary brain tumors, according to Accelerate Brain Cancer Cure, a not-for-profit organization dedicated to hastening the discovery of effective treatments for brain cancer. Less than 30 percent of patients diagnosed with primary GBMs are alive one year after diagnosis, and after 10 years, only 2.3 percent are still alive.

Even when GBMs are effectively treated with surgery or medicines, they return in more than 90 percent of all cases.

Lauren Shaftel Williams | EurekAlert!
Further information:
http://www.duke.edu

More articles from Health and Medicine:

nachricht Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>